Principal Investigator
Elizabeth Berry-Kravis, MD, PhD
Rush University Medical Center
- 4 trials
- 1 compound
Therapeutic focus
- Fragile X Syndrome
All trials (4)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05030129 | Phase 2 | Completed | — | Elizabeth Berry-Kravis |
| NCT02920892 | Phase 2 | Completed | Mavoglurant | Rush University Medical Center |
| NCT02126995 | Phase 2 | Completed | — | Alcobra Ltd. |
| NCT00788073 | Phase 2 | Completed | — | Seaside Therapeutics, Inc. |
Compounds studied
Trial sites (27)
- New Haven, Connecticut, United States
- Indianapolis, Indiana, United States
- Seattle, Washington, United States
- St Louis, Missouri, United States
- Cincinnati, Ohio, United States
- Denver, Colorado, United States
- Media, Pennsylvania, United States
- Washington D.C., District of Columbia, United States
- Staten Island, New York, United States
- Los Angeles, California, United States
- Nashville, Tennessee, United States
- Chapel Hill, North Carolina, United States
- Baltimore, Maryland, United States
- Philadelphia, Pennsylvania, United States
- Chicago, Illinois, United States
- Sacramento, California, United States
- Durham, North Carolina, United States
- Boston, Massachusetts, United States
- Ramat Gan, Israel, Israel
- Aurora, Colorado, United States
- Columbus, Ohio, United States
- Atlanta, Georgia, United States
- Phoenix, Arizona, United States
- Houston, Texas, United States
- Davis, California, United States
- New York, New York, United States
- Pittsburgh, Pennsylvania, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).